Transcription of WHO Drug Information
{{id}} {{{paragraph}}}
Example: stock market
WHO Drug Information
Pre-publication draft - page numbers are not for citation purposes 1 WHO drug Information Vol. 30, No. 1, 2016 ContentsConcept paper for comment3 A framework for risk-based identification of essential medicine products for local manufacturing in low- and middle-income countriesSafety of medicines24 The WHO Collaborating Centre for International drug Monitoring29 Look-alike sound-alike drug name confusion: trastuzumab emtansineQuality of medicines35 Quality of misoprostol productsPrequalification40 WHO rotational fellowships: an updateSafety news46 RestrictionsNicorandil: Use only as second-line angina treatment;Fosamprenavir: contraindicated with paritaprevir;Ombitasvir / paritaprevir / ritonavir: extended contraindication;Erlotinib: only for certain types of non-small cell lung cancer;47 Safety warningsThalidomide: reduced starting dose in patients over 75 years;Nintedanib: avoid in hepatic function disorder.
Pre-publication draft - page numbers are not for citation purposes 1 WHO Drug Information Vol. 30, No. 1, 2016 Contents Concept paper for comment
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: